Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.
dc.contributor.author | Booton, Richard | |
dc.contributor.author | Ward, Timothy H | |
dc.contributor.author | Heighway, Jim | |
dc.contributor.author | Taylor, Pat | |
dc.contributor.author | Power, Fiona | |
dc.contributor.author | Ashcroft, Linda | |
dc.contributor.author | Morris, Julie | |
dc.contributor.author | Thatcher, Nick | |
dc.date.accessioned | 2009-07-07T15:46:00Z | |
dc.date.available | 2009-07-07T15:46:00Z | |
dc.date.issued | 2006-06-01 | |
dc.identifier.citation | Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. 2006, 106 (11):2421-7 Cancer | en |
dc.identifier.issn | 0008-543X | |
dc.identifier.pmid | 16649224 | |
dc.identifier.doi | 10.1002/cncr.21885 | |
dc.identifier.uri | http://hdl.handle.net/10541/72863 | |
dc.description.abstract | BACKGROUND: The treatment of lung cancer has reached a therapeutic plateau. Several mechanisms of platinum resistance have been described, including the removal of platinum-DNA adduct by nucleotide excision repair (NER). Polymorphisms within the Xeroderma pigmentosum Group D protein (XPD), a member of the NER pathway, are associated with alterations in enzyme activity and may change sensitivity to platinum-based chemotherapy. The authors investigated the relation between XPD polymorphisms and treatment response, toxicity, and overall survival in patients who received platinum-based chemotherapy for advanced nonsmall cell lung cancer (NSCLC). METHODS: Between 2001 and 2002, 108 patients with chemotherapy-naive, advanced NSCLC were recruited. Associations between XPD312/751 polymorphisms and XPD haplotype and treatment response, toxicity. and survival were evaluated. RESULTS: Significant correlations were observed between XPD haplotype and Grade 4 neutropenia and overall survival together with a greater response to platinum-based chemotherapy for the XPD *A haplotype. CONCLUSIONS: The XPD haplotype may represent a useful pharmacogenomic marker of platinum-based chemotherapy in patients with advanced NSCLC and requires prospective validation. | |
dc.language.iso | en | en |
dc.subject | Lung Cancer | en |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung | |
dc.subject.mesh | DNA Repair | |
dc.subject.mesh | Female | |
dc.subject.mesh | Genotype | |
dc.subject.mesh | Haplotypes | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Lung Neoplasms | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Organoplatinum Compounds | |
dc.subject.mesh | Survival Rate | |
dc.subject.mesh | Xeroderma Pigmentosum Group D Protein | |
dc.title | Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. | en |
dc.type | Article | en |
dc.contributor.department | Christie Hospital National Health Service Trust, Manchester, United Kingdom. r.booton@btopenworld.com | en |
dc.identifier.journal | Cancer | en |
refterms.dateFOA | 2020-09-17T12:07:52Z | |
html.description.abstract | BACKGROUND: The treatment of lung cancer has reached a therapeutic plateau. Several mechanisms of platinum resistance have been described, including the removal of platinum-DNA adduct by nucleotide excision repair (NER). Polymorphisms within the Xeroderma pigmentosum Group D protein (XPD), a member of the NER pathway, are associated with alterations in enzyme activity and may change sensitivity to platinum-based chemotherapy. The authors investigated the relation between XPD polymorphisms and treatment response, toxicity, and overall survival in patients who received platinum-based chemotherapy for advanced nonsmall cell lung cancer (NSCLC). METHODS: Between 2001 and 2002, 108 patients with chemotherapy-naive, advanced NSCLC were recruited. Associations between XPD312/751 polymorphisms and XPD haplotype and treatment response, toxicity. and survival were evaluated. RESULTS: Significant correlations were observed between XPD haplotype and Grade 4 neutropenia and overall survival together with a greater response to platinum-based chemotherapy for the XPD *A haplotype. CONCLUSIONS: The XPD haplotype may represent a useful pharmacogenomic marker of platinum-based chemotherapy in patients with advanced NSCLC and requires prospective validation. |